Request Demo

Last update 26 Dec 2025

Lorazepam

Last update 26 Dec 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryLorazepam, a minute molecular compound, acts as an agonist that targets the GABAA receptor. It boasts a varied scope of medical uses, such as assuaging anxiety disorders, depressive disorder, epilepsy, sleep initiation and maintenance disorders, and even catatonia in Down Syndrome patients. Initially greenlighted by Bausch Health in 1970, this drug ushers in a binding process, whereby the GABAA receptor in the central nervous system is targeted, and subsequently leads to heightened GABAergic inhibitory neurotransmission, which deftly quashes neuronal activity and thus facilitates sedative, anxiolytic, and anticonvulsant effects. Despite the benefits of this medication, it is prudent to bear in mind the potential for adverse effects, which may include drowsiness, dizziness, and impaired coordination. With prolonged usage, there is a possibility of developing dependence on the drug, hence why it is indispensable to utilize Lorazepam only under the watchful eye of a competent healthcare provider.

Drug Type

Small molecule drug

Synonyms

Lora-Pita Intravenous, Lorazepam (JP17/USP/INN), o-Chlorooxazepam

+ [18]

Target

GABAA receptor

Action

agonists

Mechanism

GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesCongenital Disorders

Active Indication

Sleep Initiation and Maintenance DisordersSedationStatus Epilepticus+ [4]

Inactive Indication

Generalized anxiety disorder

Originator Organization

Bausch Health Cos., Inc.

Active Organization

Pfizer Japan, Inc.Hikma Pharmaceuticals USA, Inc.

The University of Colorado

+ [4]

Inactive Organization

Pfizer Inc.

Jiangsu Nhwa Pharmaceutical Co., Ltd.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (30 Sep 1977),

Anxiety DisordersDepressive Disorder

Regulation-

Structure/Sequence

Molecular FormulaC15H10Cl2N2O2

InChIKeyDIWRORZWFLOCLC-UHFFFAOYSA-N

CAS Registry846-49-1

139

Clinical Trials associated with Lorazepam

NCT06496854

/ WithdrawnPhase 2IIT

Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study

The objective of this pilot study is to discuss the feasibility of prescribing lorazepam prior to IUD insertion and of measuring effect of lorazepam on anxiety and pain with Intrauterine Device (IUD) insertion. The target population for this study will be 25 adult participants scheduled for an IUD insertion at a UW Family Medicine residency clinic. Participants will be followed for 1 appointment visit.

Start Date01 Oct 2025

Sponsor / Collaborator

University of Wisconsin-Madison

NCT06799494

/ RecruitingPhase 4IIT

Comparing the Antibody and B Cell Responses Induced by 1- or 2-dose 9-valent HPV (9vHPV) Vaccination in Healthy Adults

This study aims to answer the question: does 1-dose HPV vaccination generate the same immune responses compared to 2- or 3-dose HPV vaccination? This will be done by studying the immune response in blood, lymph nodes, and bone marrow.
Human papillomaviruses (HPV) cause cancers (cervical, anal, oropharyngeal, vulvar, vaginal, and penile), and the current HPV vaccine is highly effective at preventing disease by HPV types that cause 90% of cancer cases. While this vaccine generates high levels of antibodies that last for > 10 years, understanding of how this occurs is limited, and studying this immune response will help design new and better vaccines.
The study population consists of healthy adult (age 18-45) participants who have not previously received an HPV vaccine, do not have antibodies against certain types of HPV, do not have a history of HPV infection or disease (such as genital warts, abnormal pap test, or HPV DNA test), and do not have contraindications to study procedures. Populations of increased concern are not being enrolled.

Start Date06 Aug 2025

Sponsor / Collaborator

Emory University

[+1]

NCT07017452

/ Not yet recruitingPhase 3

Methoxyflurane + Lorazepam + Percocet (Per os) vs Deep Intravenous Sedation: A Non-inferiority Randomized Controlled Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia

The primary aim of the study is to show that methoxyflurane-lorazepam-percocet combination administrated 'per os' is non inferior to deep intravenous sedation in achieving analgesia during Rezum convective radiofrequency water vapor thermal therapy for the management of benign prostate hyperplasia (BPH). We propose to conduct a single-centered, unblinded, randomized controlled trial designed after consulting ICH Guidelines for Good Clinical Practice as well the regulations set by the Biomedical Research Ethics Board, University of Manitoba.

Start Date01 Aug 2025

Sponsor / Collaborator

University of Manitoba

100 Clinical Results associated with Lorazepam

100 Translational Medicine associated with Lorazepam

100 Patents (Medical) associated with Lorazepam

7,226

Literatures (Medical) associated with Lorazepam

01 Jan 2026·AMERICAN JOURNAL OF EMERGENCY MEDICINE

Benzodiazepine-refractory status epilepticus: A narrative review

Review

Author: Koyfman, Alex ; Pelletier, Jessica ; Long, Brit ; Merriman, Walter

INTRODUCTION:

Seizures are a common complaint in the emergency department, with status epilepticus (SE) associated with significant morbidity and mortality. While the typical first-line therapy for seizures includes benzodiazepines, patients with SE may be refractory to benzodiazepines. Seizures of longer duration are harder to break, and SE becomes a self-sustaining cycle; thus, benzodiazepine-refractory SE is a particularly challenging condition facing emergency clinicians.

OBJECTIVES:

This narrative review provides a focused evaluation of SE refractory to first-line therapy, highlighting potential underlying causes and management strategies.

DISCUSSION:

SE may occur in 22 % of seizure cases presenting to the emergency department, and up to 40 % of these patients will have seizure activity refractory to benzodiazepine therapy. Prolonged seizure activity is associated with long-term neurologic consequences. Potential underlying causes of SE include endocrine, metabolic, infectious, neurologic, obstetric, toxicologic, and traumatic etiologies. Reversing these underlying causes can help terminate seizure activity. Benzodiazepines (lorazepam, diazepam, and midazolam) are considered first-line anti-seizure medications (ASMs) and must be administered in adequate doses to reach their maximum therapeutic potential. Patients who continue seizing should receive a second dose of benzodiazepines at the 5-min mark, combined with a second-line ASM, such as fosphenytoin (preferred over phenytoin), levetiracetam, or valproic acid. Patients who continue seizing are considered to have refractory SE and should receive third-line agents, such as ketamine, pentobarbital, propofol, or thiopental, as the clinician prepares for intubation. Continuous electroencephalography (EEG) should be considered when moving from second- to third-line ASMs or when intubation is necessary. Early aggressive therapy is key for terminating seizure activity.

CONCLUSION:

Recognizing and treating SE early is critical for preserving neurologic function. Emergency clinicians must be prepared to reverse the underlying causes of SE and utilize second- and third-line ASMs to abort seizure activity when necessary.

01 Dec 2025·Acta Epileptologica

Psychiatric disorders with antiseizure medications in children: an analysis of the FDA adverse event reporting system database

Article

Author: Jiang, Li ; Meng, Linxue ; Wang, Lingman ; Gui, Jianxiong ; Zhang, Xiaofang ; Ma, Jiannan

Abstract:

Background:

Epilepsy is a chronic neurological disorder marked by a persistent tendency to generate seizures, leading to substantial cognitive, behavioral, and psychosocial consequences. This study investigated psychiatric disorder-related adverse events (AEs) associated with antiseizure medications (ASMs) in children using the Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Methods:

This study conducted a comprehensive analysis of FAERS data from 2004 to 2024, focusing on psychiatric AEs in children with epilepsy or seizures treated with ASMs. Signal values were computed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-item Gamma Poisson Shrinker (MGPS).

Results:

A total of 2539 preferred terms (PTs) were included, involving 25 system organ classifications (SOCs). Nervous system, skin and subcutaneous tissue, and psychiatric disorders are the three most common SOCs for ASMs in children. There were 24 ASMs, whose AEs involved psychiatric disorders, totaling 110 PTs and 214 drug-PT relationships. Psychotic symptoms (notably lorazepam and topiramate, n = 116 and 109), substance dependence and abuse (notably pregabalin and clonazepam, n = 291 and 110), and the other neuropsychiatric symptoms (notably levetiracetam and valproic acid, n = 70 and 62) were the common types of psychiatric disorder-related AEs of ASMs in children. A total of nine ASMs (brivaracetam, clonazepam, diazepam, eslicarbazepine, gabapentin, lamotrigine, lorazepam, perampanel, and tiagabine) were associated with suicidal and self-injurious behavior in children.

Conclusions:

This study highlights psychiatric AEs of ASMs in children, offering critical insights to improve clinical medication practices and enhance treatment safety. Further research with broader clinical data is needed to promote safe and rational medication use.

01 Dec 2025·JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Development and validation of a LC–MS/MS method for the detection of 38 benzodiazepines and 2 Z-drugs in blood

Article

Author: Liu, Xin-Ze ; Liu, Yu ; Guo, Zhen-Shuo ; Yan, Hui ; Xiang, Ping

Benzodiazepines and Z-drugs are commonly used as prescription medications to treat anxiety, epilepsy, insomnia, and alcohol withdrawal syndrome, but their use can lead to tolerance, dependence, and withdrawal reactions if taken against official guidelines. Furthermore, designer benzodiazepines, most of which lack clinical and toxicological data, have entered the illicit drug market as new psychoactive substances and are used for recreational purposes. Their abuse can cause confusion, memory loss, respiratory depression, and even death, especially when combined with other sedative-hypnotics or alcohol. Therefore, new qualitative and quantitative methods for benzodiazepines and Z-drugs are needed for use in forensic and clinical toxicology. This study explored the sample preparation and liquid-liquid extraction using 0.5 mL blood samples and 2 mL of extraction solvent for analysis of these drugs by liquid chromatography-tandem mass spectrometry and multiple reaction monitoring. The benzodiazepines were separated on a pentafluorophenylpropyl (PFPP) column using a mobile phase gradient consisting of A (water, 0.1 % formic acid, 5 % acetonitrile, and 20 mmol/L ammonium acetate) and B (acetonitrile) for 9 min. Validation steps confirmed that the method demonstrated good selectivity, sensitivity (limit of detection: 0.2 ng/mL, lower limit of quantification: 0.5 ng/mL), linearity (R² ≥ 0.99), accuracy, and precision (<20 %). Matrix effects ranged from 35 to 126 %, and recoveries ranged from 17 to 99 %, with 35 compounds having recoveries of more than 50 %. The method was successfully applied for the identification and quantification of benzodiazepines and nonbenzodiazepines in blood samples from 15 authentic poisoning cases. Ten analytes were detected: alprazolam (130.2-575.3 ng/mL), hydroxyalprazolam (2.3-37.3 ng/mL), clonazepam (11.7-773.2 ng/mL), lorazepam (63.4-166.9 ng/mL), 7-aminoclonazepam (17.4-385.3 ng/mL), oxazepam (2.6-964.1 ng/mL), diazepam (227.2 ng/mL), nordazepam(22.4 ng/mL), zolpidem (11.8-64.0 ng/mL), midazolam (70.2 ng/mL), and hydroxymidazolam (162.8 ng/mL).

News (Medical) associated with Lorazepam

19 Nov 2025

·www.einpresswire.com

JustAnswer Reveals Dramatic Shifts in Prescription Drug Concerns as Mental Health and GLP-1 Meds Dominate Queries

Over 115,000 prescription-related questions fielded on JustAnswer in 2025; weight loss drug queries surge 56% since 2023, while birth control questions dip 63% This data highlights people's desire to get immediate, trustworthy answers about drugs they’re hearing about in the news and online — whether it’s a weight-loss medication or an anxiety prescription.” — Andy Kurtzig, CEO & Founder of JustAnswer SAN FRANCISCO, CA, UNITED STATES, November 19, 2025 / EINPresswire.com / -- Consumers are increasingly turning to online medical experts to navigate complex medication choices — from trending GLP-1 medications to rising questions about anxiety and hormone treatments — according to new data from JustAnswer, the world’s largest expert platform . JustAnswer experts have fielded more than 115,000 prescription-related questions so far in 2025, but it’s the pivot in what consumers are actually asking about that reveal how dramatically patient concerns are evolving. Specifically, questions about anxiety medications, weight-loss drugs and hormone therapy have surged to dominate the conversation, while interest in categories like birth control has steadily declined. In addition, JustAnswer data showed evidence about emerging curiosity and/or discussion about medications linked to autism causes and possible treatment. “What we’re seeing is a fundamental reshaping of prescription priorities,” said JustAnswer Founder and CEO Andy Kurtzig. “People are more proactive and curious than ever — asking about new medications they’ve seen in the media, managing shortages, or trying to understand side effects and alternatives. This is one of the reasons we recently launched JustAnswer Pharmacy as an extension of our telehealthcare offering after having these conversations with our physicians.” GLP-1 Drug Questions Continue to Skyrocket Fueled by social media buzz and expanding drug availability, questions about Ozempic, Mounjaro, Wegovy, and other GLP-1 medications have risen more than 56% since 2023, hitting record highs in 2025. - Mounjaro inquiries more than doubled (+142%) from 2023 to 2025 — the fastest growth of any weight-loss drug. - Wegovy also saw a 118% increase, while Ozempic remains the most-asked-about drug overall (2,504 questions since 2023). The largest spike in this category on JustAnswer came in September 2025, coinciding with renewed public debate over shortages and widespread media coverage of celebrity use. Mental Health Medication Questions Rebound Late in 2025 Questions about Xanax, Adderall, Lorazepam, and antidepressants continue to make up one of the most active prescription categories on JustAnswer, totaling more than 13,000 questions since 2023. After a dip in 2024, question volume rebounded in late 2025, mirroring broader public conversations about stress, ADHD, and anxiety. - Xanax remains the top-searched mental health medication, accounting for 40% of all mental health–related questions (5,506 total). - Adderall inquiries declined (–31% since 2023), but 2025 saw a rebound during back-to-school and work transitions. - Mentions of Lorazepam rose notably in early 2025, coinciding with its appearance in The White Lotus TV series. Hormone Therapy Sees a Late-Year Rebound Although total hormone-related questions on JustAnswer declined slightly over the past three years (–21% from 2023 to 2025), the trend turned upward again in 2025, especially for hormone replacement therapy (HRT) – likely influenced by broad media coverage and increased advertising in the menopause telehealth space. - HRT inquiries increased 21% year-over-year in 2025, peaking in September. - Broader “Hormone Therapy” questions rose 34% since 2023, suggesting growing awareness of treatment options beyond testosterone, which still accounts for 72% of all hormone-related inquiries. Emerging Curiosity Around Medications Linked to Possible Autism Causes and Treatment While not a prescription drug, one OTC medication did see a meaningful increase within the data. Tylenol questions rose significantly in late 2025, peaking in September, aligning with the public debate sparked by comments from Donald Trump and Robert F. Kennedy Jr. claiming a link between acetaminophen and autism. On the other end of the autism discussion, another drug saw a singular spike this fall: Leucovorin, a medication sometimes discussed in relation to autism, received 1,200% more questions YOY in 2025, peaking in October. This marks the sharpest growth in any prescription drug category on the platform and likely reflects new awareness generated by the MAHA movement, online communities and media discussions around emerging off-label uses for treatment of autism in children. Category in Decline: Birth Control On the other hand, questions about birth control, Mifepristone, and Misoprostol have declined on JustAnswer by 63% since 2023, signaling reduced public engagement with these medications. “Overall, this data highlights the desire for people to get immediate, trustworthy answers about new drugs they’re hearing about in the news and online — whether it’s a weight-loss medication or an anxiety prescription — and platforms like ours give them that access in real time,” said Kurtzig. “And now with JustAnswer Pharmacy, they also have a convenient, affordable way to acquire these and many prescription medications they need under medical supervision.” About JustAnswer JustAnswer is the world’s largest expert platform that connects people with live doctors, lawyers, vets, mechanics, and other verified professionals for real-time, online help. Featuring more than 20,000 experts across 150 categories, JustAnswer has helped millions of customers across 196 countries since 2003. Aimee Grove Smitten Communications aimee@smittencomm.com Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

17 Nov 2025

·www.drugs.com

Hit HBO Series Doubled Internet Searches For An Addictive Benzodiazepine

MONDAY, Nov. 17, 2025 — Life imitates art, the saying goes, but does that extend to TV depictions of prescription drug misuse? The last season of the HBO hit series " The White Lotus " might have inadvertently increased interest in a powerful anti-anxiety medication, a new study says. Internet searches regarding lorazepam doubled following the series’ third season, which started airing in February, researchers reported Nov. 14 in JAMA Health Forum . This increase was not observed for other commonly prescribed benzodiazepines like alprazolam or clonazepam , which weren’t mentioned on the show, researchers said. “We saw significant increases in searches related to acquiring lorazepam,” said senior researcher Eric Leas , an assistant professor at the University of California-San Diego Herbert Wertheim School of Public Health and Human Longevity Science. “It shows that there might be a subset of people that are actually wanting to figure out how to obtain that medication online,” Leas added in a news release. One of the characters on the show, Victoria Ratliff, takes lorazepam to help with social anxiety and sleep problems. Her husband, Timothy, starts sneaking her pills to cope with the stress of a financial scandal that’s brewing back home while he’s on vacation in Thailand. “Not only would he take it, but he would also combine it with alcohol, which we know is very dangerous,” lead researcher Dr. Kevin Yang said in a news release. He’s a resident physician of psychiatry at the UC-San Diego School of Medicine. Both characters become visibly loopy taking lorazepam, slurring their words, slumping into sleep at the dinner table and staggering as they walked. For the new study, researchers analyzed Google search data for lorazepam, alprazolam and clonazepam from January 2022 through June 2025. They found that searches regarding lorazepam spiked by an extra 1.6 million for a 12-week period after the third season of "The White Lotus" began – levels nearly 99% higher than would be expected given prior search trends. Searches indicating an attempt to acquire lorazepam also increased to levels nearly 64% higher than usual, representing an additional 30,000 searches. “For the treatment of anxiety, lorazepam is typically prescribed for the short term because long-term use can lead to tolerance and dependence as well as misuse,” Yang said. “Studies have shown that almost 1 in 5 people who are prescribed benzodiazepines eventually end up misusing them.” Yang said he’s particularly concerned that the show didn’t fully explore the risks of taking lorazepam, such as addiction or overdose. “It didn't really portray any of the adverse effects that might come from taking too much or from stopping it all of a sudden,” he said. In the future, shows depicting drug use might consider including warnings at the beginning and the end of each episode, to better inform impressionable viewers, Yang said. Viewers also can help themselves by approaching depictions of drug use with some skepticism, he added. ”My suggestion would be to take everything that is portrayed in the media, whether that's on TV, film or in music, with a grain of salt,” Yang said. “It's only showing one aspect of the medication, and that there are possible downsides. But ultimately, for things like medications, it's important to talk with your doctor.” Sources University of California-San Diego, news release, Nov. 14, 2025 JAMA Health Forum, Nov. 14, 2025

Drug Approval

28 Jul 2025

·www.prnewswire.com

Standard drug screening fails to identify some children who have been exposed to substances in unsafe home environments

New findings at ADLM 2025 could remedy this CHICAGO, July 28, 2025 /PRNewswire/ -- According to research presented today at ADLM 2025 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), standard drug screening misses low concentrations of targeted substances in around 5% of urine samples taken from patients under age 18, suggesting that children with drugs in their systems are sometimes released from healthcare settings into unsafe home environments. The study highlights an adjustment that clinical labs can make to improve the accuracy of results and to help ensure that substance-exposed children and their families get appropriate support. Researchers have long known that standard urine drug screening (UDS) — which is typically done using a technique known as immunoassay — can sometimes trigger false positives, or erroneous results that indicate the presence of a drug when there isn't one. It's the reason a second confirmatory test with mass spectrometry is typically used to verify results for patients who test positive on immunoassay. However, the opposite issue, where UDS indicates an absence of drugs in patients who have actually taken them (false negatives), has not been well studied. This mistake is more likely to occur in samples taken from infants and young children whose kidneys are still developing or who have incidental exposure to a low level of drugs, resulting in a low drug concentration in their urine that may not reach the cutoff used in standard UDS. One approach for minimizing this possibility is to use mass spectrometry on all pediatric patients, skipping the initial immunoassay. "To our knowledge, St. Louis Children's is the only hospital in the U.S. to adopt this 'direct-to-mass-spectrometry' approach," said Dr. Yanchun Lin, one of the study's authors and a clinical chemistry fellow at Washington University in Saint Louis, Missouri. "So we really want to urge laboratorians to reconsider the approach they adopt for pediatric UDS testing." The researchers used two strategies to compare immunoassay results with mass spectrometry for detecting substances in common drug tests, including amphetamine/methamphetamine, cocaine/benzoylecgonine (the main metabolite of cocaine), THC, opiates, fentanyl, benzodiazepines, and methadone. In the first approach, they studied 125 urine samples over a 5-month period from pediatric patients with weakly positive results on mass spectrometry to check how many of them were missed by immunoassay (forward approach). For the second strategy, they assessed 115 urine samples that tested negative on immunoassay to assess if mass spectrometry could detect any drugs (reverse approach). Among the 125 samples that tested positive on mass spectrometry, 112 (approximately 90%) contained compounds not detected by immunoassay, most commonly methamphetamine and benzoylecgonine. Thirty-eight (33%) of the 115 samples found negative on routine UDS tested positive for at least one substance when re-examined by mass spectrometry. Moreover, mass spectrometry identified substances in six samples (5%) that were targeted but missed by immunoassay. In addition, the researchers identified 32 pediatric urine samples that contained prescription medications not picked up by immunoassay, including lorazepam, ketamine, bupropion, methylphenidate, clonidine, quetiapine, venlafaxine, and naloxone. They also found five samples containing fentanyl, which wasn't on the UDS menu at some study centers from which samples were taken. Taken together, the results indicate that UDS may miss low drug concentrations in approximately 1 in 20 pediatric urine samples. This finding held true using both the forward and reverse schemes, spanning multiple clinical environments and analytic platforms. Using a direct-to-mass spectrometry approach would significantly lessen the risk of false-negative drug screens and largely eliminate false-positive findings as well, the authors conclude. That said, making this change isn't without challenges for labs. "It's actually pretty labor intense," Lin said, "and it's much harder to maintain the assay" using the direct-to-mass spectrometry approach. "You need highly trained personnel and dedicated full-time employees," she added. But labs that can make the shift will benefit from more accurate results that could translate to better care. "If it's possible, it should definitely be adopted, especially for pediatric patients," Lin said. Session information ADLM 2025 registration is free for members of the media. Reporters can register online here: Abstract A-349: False-negative immunoassay drug screens uncovered with a direct to mass spectrometry approach in a pediatric population will be presented during: Student poster competition Monday, July 28 9:30 a.m. – 4 p.m. Room S405 Scientific poster session Tuesday, July 29 9:30 a.m. – 5 p.m. (presenting authors in attendance from 1:30 – 2:30 p.m.) Poster Hall on the Expo show floor Both sessions will take place at McCormick Place, Chicago. About ADLM 2025 ADLM 2025 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo) offers 5 days packed with opportunities to learn about exciting science from July 27-31 in Chicago. Plenary sessions will explore urgent problems related to clinical artificial intelligence (AI) integration, fake medical news, and the pervasiveness of plastics, as well as tapping into the promise of genomics and microbiome medicine for personalized healthcare. At the ADLM 2025 Clinical Lab Expo, more than 800 exhibitors will fill the show floor of the McCormick Place Convention Center in Chicago, with displays of the latest diagnostic technology, including but not limited to AI, point-of-care, and automation. About the Association for Diagnostics & Laboratory Medicine (ADLM) Dedicated to achieving better health for all through laboratory medicine, ADLM (formerly AACC) unites more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from 110 countries around the world. Our community is at the forefront of laboratory medicine's diverse subdisciplines, including clinical chemistry, molecular diagnostics, mass spectrometry, clinical microbiology, and data science, and is comprised of individuals holding the spectrum of lab-related professional degrees, certifications, and credentials. Since 1948, ADLM has championed the advancement of laboratory medicine by fostering scientific collaboration, knowledge sharing, and the development of innovative solutions that enhance health outcomes. For more information, visit . Christine DeLong ADLM Director, Editorial and Media Relations (p) 202.835.8722 [email protected] Bill Malone ADLM Senior Director, Strategic Communications (p) 202.835.8756 [email protected] SOURCE Association for Diagnostics & Laboratory Medicine (ADLM) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultClinical Study

100 Deals associated with Lorazepam

External Link

KEGG	Wiki	ATC	Drug Bank
D00365	Lorazepam	N05BA06	DB00186

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Sleep Initiation and Maintenance Disorders	China	Hunan Dongting Pharmaceutical Co., Ltd.	10 Oct 2003
Sedation	United States	Hikma Pharmaceuticals USA, Inc.	25 Jul 1980
Status Epilepticus	United States	Hikma Pharmaceuticals USA, Inc.	25 Jul 1980
Catatonia	Japan	Pfizer Japan, Inc.	04 Nov 1977
Anxiety Disorders	United States	Bausch Health US LLC	30 Sep 1977
Depressive Disorder	United States	Bausch Health US LLC	30 Sep 1977

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Down Syndrome	Phase 2	United States	The University of Colorado	22 Dec 2022
Generalized anxiety disorder	Clinical	United States	Pfizer Inc.	01 Oct 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00721526 (CTgov)	Phase 4	Alcoholism \| Drug-induced anxiety disorder \| Anxiety Disorders ... View more	41	disulfiram+lorazepam	pxhxifmpes = eqassttinj mjgemeydhy (flispkptly, borstrzbtb - figntbespq) View more	-	30 Aug 2023
NCT03435692 (CTgov)	Not Applicable	Pain, Postoperative	42	ropivacaine (Lumbar Epidural Catheter (< 6 Years Old))	djwlvmtcvh(ciucgxntjj) = acualaskfn dljcjexmpi (rmdlhgmqbd, 0.5) View more	-	02 Nov 2021
				ropivacaine (Lumbar Plexus Catheter (< 6 Years Old))	djwlvmtcvh(ciucgxntjj) = noauxqdbcu dljcjexmpi (rmdlhgmqbd, 0.8) View more
NCT03090620 (TAAT, CTgov)	Phase 4	Toxicity	19	Physostigmine (Physostigmine)	zbjihdwbsc(nmblzslihn) = phpzvckqyq ywgdekszol (mgvakqjcup, jttpejhmqy - nqfbcphtjt) View more	-	23 Aug 2021
				Lorazepam (Lorazepam)	zbjihdwbsc(nmblzslihn) = waazpzcbuc ywgdekszol (mgvakqjcup, emwtlmrgzd - cgxumgmzrs) View more
NCT01949662 (CTgov)	Phase 2	Delirium \| Advanced cancer	93	Lorazepam+Haloperidol (Intervention Group (Lorazepam & Haloperidol))	fgzphaabwz(lnmwjbpfms) = tjviuylhos sruyhatbcs (ezlulnbxaf, qyhsjapehw - xzajdvvcsb) View more	-	30 Oct 2020
				Placebo+Haloperidol (Control Group (Placebo & Haloperidol))	fgzphaabwz(lnmwjbpfms) = pmvxvjgicv sruyhatbcs (ezlulnbxaf, pcewolajsj - mlzradbuoi) View more
NCT03202550 (OSDI, CTgov)	Phase 4	Pain	27	Placebo Comparator (Placebo Arm)	kfrttgybkn(oklgqghgxt) = kffoijvirh eqhbuucmth (pjmijcudvx, syxzawrepd - luimhsbtpq) View more	-	06 Mar 2020
				Lorazepam+Oxycodone (Active Drug Arm: Lorazepam and Oxycodone)	kfrttgybkn(oklgqghgxt) = mbcpeutjkt eqhbuucmth (pjmijcudvx, gclbxjcyyx - qlynjbodgm) View more
NCT03756038 (CTgov)	Phase 2	Respiratory Distress Syndrome \| Acute Pain	1	Lorazepam (Drug: Oral Lorazepam (1mg))	jbvygzubwj = jkgiyibruq iquvxvxlvl (bmzojzrquv, myglpchwde - ksucsbvkhe) View more	-	26 Feb 2020
				Placebos (Drug: Oral Placebo)	usdvkxiwgp(hkdphapjcr) = hmnfibmzjk qaqbduczfu (korxhvfxeg, zmpoqqjqrw - jwcdbblfko) View more
NCT03180632 (Pubmed \| Paediatr Drugs)	Phase 2	-	101	Oral Lorazepam	xhzycahknh(vvfvgcrena) = bqhoarstpo fjvzydanct (saulekxeze ) View more	Positive	01 Oct 2019
				Placebo	xhzycahknh(vvfvgcrena) = peqzksfuat fjvzydanct (saulekxeze ) View more
NCT00457366 (CTgov)	Phase 4	Agitation	72	Quetiapine	dxlhevnkmi(kxqkxsuruz) = jypjtqjbwp hejbctookz (sdfakskfjd, 0.69) View more	-	05 Jul 2019
NCT01330459 (CTgov)	Phase 4	Pain	121	Hydrocodone/acetaminophen+Lidocaine+Ibuprofen+Lorazepam (Hydrocodone/Acetaminophen)	bcheqyuycr(yiperwgvxd) = prixyqcxsh rlvkpemqoe (egucrbornd, 25.4) View more	-	26 Apr 2019
				Placebo+Lidocaine+Ibuprofen+Lorazepam (Placebo)	bcheqyuycr(yiperwgvxd) = xcivsqoqai rlvkpemqoe (egucrbornd, 26.6) View more
NCT01067144 (Pubmed \| JAMA Netw Open)	Phase 3	Lung Cancer \| Pain \| Breast Cancer	422	Gabapentin	shjkfpqmiw(eejdmumoco): HR = 0.83 (95% CI, 0.78 - 0.87)	-	01 Mar 2019
				Active placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis